205242-64-4

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-(benzylamino)-3-(benzyloxy)propan-2-ol is used as a potential pharmaceutical candidate for various applications due to its unique structure and functional groups. The benzylamino and benzyl ether groups may contribute to its interaction with biological targets, making it a promising molecule for the development of new drugs.
Used in Medicinal Chemistry:
(S)-1-(benzylamino)-3-(benzyloxy)propan-2-ol is used as a building block or intermediate in the synthesis of more complex molecules for medicinal chemistry. Its chiral nature and functional groups can be further modified or combined with other compounds to create new pharmaceutical agents with specific therapeutic properties.
Used in Synthetic Chemistry:
(S)-1-(benzylamino)-3-(benzyloxy)propan-2-ol is used as a versatile starting material in synthetic chemistry for the preparation of various organic compounds. Its unique structure and functional groups can be utilized in a wide range of chemical reactions, enabling the synthesis of diverse molecules with potential applications in various fields.

Upstream product

• 2930-05-4 (S)-benzyl glycidyl ether 
• 100-46-9 benzylamine 
• 14618-80-5 (R)-benzyl glycidol 

Downstream Products

• 205242-65-5 (S)-4-Benzyl-6-benzyloxymethyl-morpholin-3-one 
• 205242-66-6 (2S)-4-(phenylmethyl)-2-{[(phenylmethyl)oxy]methyl}morpholine 

Relevant academic research and scientific papers

HIV PROTEASE INHIBITORS

The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

(R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine methanesulfonate: A new selective rat 5-hydroxytryptormine(1b) receptor antagonist

In the search for new 5-hydroxytryptamine (5-HT) receptor antagonists it was found that the compound (R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8- yl]oxy]methyl]morpholine methanesulfonate, (R)-25, is a selective rat 5- hydroxytryptamine(1B) (r5-HT(1B)) receptor antagonist. The binding profile showed a 13-fold preference for r5-HT(1B) (Ki = 47 ± 5 nM; n = 3) vs bovine 5-HT(1B) (Ki = 630 nM; n = 1) receptors. The compound had very low affinity for other monoaminergic receptors examined. The r5-HT(1B) receptor antagonism was demonstrated by the potentiation of the K+-stimulated release of [3H]- 5-HT from superfused rat brain slices in vitro, an effect that was antagonized by addition of 5-HT to the superfusion fluid. (R)-25 at 20 mg/kg sc enhanced the 5-HT turnover in four rat brain regions (hypothalamus, hippocampus, striatum, and frontal cortex) with about 40% measured as the 5- HTP accumulation after decarboxylase inhibition with 3- hydroxybenzylhydrazine. At 3 mg/kg sc (R)-25 produced a significant increase in the number of wet dog shakes in rats, a 5-HT(2A)/5-HT(2C) response that was abolished by depletion of 5-HT after pretreatment with the tryptophan hydroxylase inhibitor p-chlorophenylalanine. The observations show that (R)- 25, by inhibiting terminal r5-HT(1B) autoreceptors, increases the 5-HT turnover and the synaptic concentration of 5-HT.